All about APOBEC3G

A gap caused during DNA replication could result in cancer-causing mutations

Register for free to listen to this article
Listen with Speechify
BLOOMINGTON, Ind.—Recent work at Indiana University (IU) has identified a genetic mechanism that likely plays a role in driving mutations that can lead to cancer.
The study, which appeared Feb. 1 in the Proceedings of the National Academy of Sciences, finds the enzyme APOBEC3G appears to initiate these changes by mutating genes during the replication of DNA. APOBEC3G is a known trigger for mutations that occur as benign tumor cells transform into cancerous malignancies that spread throughout the body.
“There is a uniquely vulnerable point in the DNA ligand strand,” says Patricia Foster, the principal investigator on the grant and a professor in the IU Bloomington College of Arts and Sciences’ Department of Biology and senior author on the study.
The research was conducted in the bacteria Escherichia coli, with support in part from IU’s $6.2-million grant to investigate bacterial evolution from the U.S. Army Research Office. The Wayne State University School of Medicine, whose researchers provided expertise on APOBEC3G and helped analyze the data, also supported the study. All experiments were carried out at IU. E. coli allows scientists to monitor genetic changes over thousands of generations in a relatively short time span. The results apply to humans as well, since the basic mechanisms of DNA replication are the same across all species.
“Many tumors accumulate mutations during their growth, which leads to the subsequent characteristics that permit metastasis,” Foster said. “Based upon the results revealed in bacteria in our study, we believe that the APOBEC family of enzymes creates some of these mutations specifically during the rapid growth of these tumors.” These enzymes, she notes, target single-strand DNA.
The next step, Foster says, is how cytosine deamination, when removed in favor of oxygen, becomes uracil—which, if not repaired, introduces mutations.
The results could have implications for personalized medicine. Since it is possible to identify tumors potentially vulnerable to the enzyme by using current DNA sequencing technology, a physician treating these tumors might want to explore temporarily suppressing expression of this enzyme, Foster noted.
The APOBEC family of enzymes normally plays an important role in the human immune system by driving changes in immune cells that help in the defense against viruses. The IU researchers found that the harmful influence of this enzyme family arises from the way that two halves of every double-stranded DNA molecule must unravel to replicate—splitting into two temporarily single-stranded DNA chains thousands of “links” in length to serve as templates for the new copy.
These links are the four chemicals, or nucleobases, that comprise all DNA: cytosine (C), guanine (G), adenine (A) and thymine (T). As these paired chemicals are split in half to be copied, one of the two single-stranded bits of DNA—known as the lagging strand template—is highly vulnerable to genetic mutation, Foster said.
This “gap in the armor” occurs because the enzyme responsible for building a new string of DNA, known as a DNA polymerase, must repeatedly traverse the nucleobases in the lagging strand template thousands of times during the course of replication, stopping further down the chain from the base pair previously inserted on the past loop along the chemical chain. Each of these polymerase “hops” creates a long stretch of DNA that temporarily remains as a single strand.
Adding to the issue is the fact that the two DNA strands are oriented in opposite directions, and polymerases copy in only a single direction. The process introduces more opportunities for errors in the lagging strand template compared to the continuous, step-by-step process that replicates the other half of the split strand of DNA, called the leading strand template.
“We’re talking about thousands of bases exposed without a complementary strand throughout the whole replication cycle,” Foster said. “If I were going to design an organism, I would make two types of copying enzymes, one that could go each way. But that’s not how it works; no organism has ever evolved a more efficient way to replicate DNA.”
The APOBEC family of enzymes drives mutation via cytosine deamination, in which a cytosine transforms into uracil, one of the four bases in RNA that doesn’t play a role in DNA replication. The presence of uracil during DNA replication can cause an error when a thymine replaces a cytosine, and APOBEC enzymes specifically target the C’s in single-stranded DNA for deamination.
The disruptive effect of the enzyme on genetic replication in the study was observed in a strain of E. coli whose ability to remove the dangerous uracils had been switched off. To conduct the experiment, Foster’s lab observed the effect of APOBEC3G on approximately 50 identical lineages of E. coli over the course of nearly 100 days, with each day encompassing 20 to 30 bacterial generations.
A unique pattern of nucleotides was detected in the mutated DNA, a chain of three cytosine molecules, or C-C-C, the same genetic signature found in other studies of the enzyme family. These mutations were four times more likely to be found on the lagging-strand template than on the leading-strand template, results that “strongly suggest that these mutations occur as APOBEC3G attacks cytosines during DNA replication, while they’re most exposed on the lagging strand template,” Foster said.

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN July 2024 Magazine Issue

Latest Issue  

• Volume 20 • Issue 4 • July 2024

July 2024

July 2024 Issue